2cureX plans to get listed at Nasdaq Stockholm First North stock exchange in November 2017.
2cureX AB (“2cureX”) announces today that the company plan a public issue of shares ahead of applying to get listed at the Nasdaq Stockholm First North. 2cureX is in the process of launching a clinical validation trial on colorectal cancer patients in Denmark, Germany and the UK. A successful outcome of this trial will pave the way for market launch of the IndiTreat™ product.
2cureX is a MedTech company that has developed IndiTreat™, a technology that can match the individual cancer patient with an efficacious treatment. IndiTreat™ has been developed and tested in more than 900 patients with promising results. Initially IndiTreat™ is directed towards colorectal cancer; but it has successfully been pre-tested in other solid cancers. 2cureX has test sites at University Hospital Bispebjerg, in Copenhagen and at University Medical Center Hamburg-Eppendorf in Hamburg.
Dr. Ole Thastrup, CEO of 2cureX commented: “We are extremely excited about moving 2cureX to the next level as a publicly traded company. 2cureX has been fortunate to have dedicated private investors since its inception in December 2006, and to work closely with exceptionally competent clinicians at hospitals in Denmark and Germany. The proximity to the real customers, the patients, has had a major impact on our ability to develop a functional end-point test. The IndiTreat™ test allows oncologists to test available treatments on the growth of micro-tumors originating from the patient’s cancer tumor. In our previous clinical studies, we have shown that IndiTreat™ not only can identify the most effective treatment; but also, the treatment to which the patient is resistant.
In late stage cancer it is extremely important to choose the right treatment up-front, which will require the right set of tools to be used by the oncologist. In 2cureX we are convinced that IndiTreat™ will become an indispensable piece of the oncologist’s toolbox.”
The Chairman of the Board of Directors of 2cureX, Povl-Andre’ Bendz further adds: “We believe that the timing for a public listing is just right for 2cureX. The IndiTreat™ test is matured to a stage where it is ready for the final clinical validation. A successful clinical trial will provide a clear value inflection point for the company. We look forward to see that 2cureX will perform well at the Nasdaq Stockholm First North.”
In 2017 2cureX has been selected to receive EUR 3 mio from EU’s H2020 program to cover the expenses for running above mentioned clinical validation study.
For further information please contact
Dr. Ole Thastrup
CEO, 2cureX AB
Tel: +45 2211 5399
2cureX is a MedTech company that has developed a technology called IndiTreat™. IndiTreat™ can identify the effective medical treatment for the individual cancer patient. The first IndiTreat™ product is focussed on colorectal cancer. Subsequent products will address other solid cancers like ovarian, breast and kidney.